4564.T
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.
The company maintains a strong liquidity position, with cash and equivalents amounting to 833,883,000 JPY, significantly exceeding its total liabilities of 426,092,000 JPY, as reflected in a current ratio of 3.37. The price-to-book ratio of 11.48 indicates that the market is valuing the company's equity at a premium relative to its book value. However, the company's operating cash flow is negative at -815,021,000 JPY, suggesting that it is not generating sufficient cash from operations to sustain its activities.
Profitability metrics are concerning, with a net loss of 815,285,000 JPY and a return on equity of -1.1182, indicating that the company is not generating returns for its shareholders. The return on assets of -0.7058 further underscores the inefficiency in asset utilization to generate profits. The company's gross profit is also negative at -12,756,000 JPY, highlighting the challenges in managing production and operational costs.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risks if the segment or region experiences a downturn. The company's operating income is negative at -796,015,000 JPY, indicating that it is not profitable from its core operations.
The company's growth trajectory is uncertain, with a net loss in the most recent fiscal year and no clear indication of improvement in the near term. The operating income and net income are both negative, suggesting that the company is not on a path to profitability. The company's capital expenditure is relatively low at -279,000 JPY, indicating minimal investment in long-term assets.
The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The debt-to-equity ratio of 0.07 suggests that the company is not heavily leveraged, reducing its financial risk. The company's capital structure is primarily equity-based, with total equity of 729,111,000 JPY and long-term debt of 51,067,000 JPY.
Recent events, as disclosed in the company's financial filings, do not indicate any significant changes in its business operations or financial position. The company's market price is 21.0 JPY, and its market capitalization is 8,371,515,012 JPY, reflecting the market's perception of its value. The company's shares outstanding are 398,643,572, with no difference between basic and diluted shares, indicating no significant dilution risk.
- The company has a strong liquidity position with a current ratio of 3.37 and significant cash reserves.
- The company is not profitable, with a net loss of 815,285,000 JPY and negative returns on equity and assets.
- The company's revenue is concentrated in a single business segment, increasing its exposure to market risks.
- The company's growth trajectory is uncertain, with no clear path to profitability in the near term.
- The company has low liquidity and dilution risks, with a debt-to-equity ratio of 0.07.
- **margin_outlook_rationale**: The company's gross profit is negative, indicating that it is not able to cover its production costs, which is a significant concern for its margin outlook.
- **rd_outlook_rationale**: The company's financial statements do not provide specific information on research and development expenditures, making it difficult to assess the outlook for R&D.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 4564.T Market data — financials · 2026-05-26
- OncoTherapy Science Inc Market data — analyst estimates · 2026-05-26